Differential effects of organic nitrates on arterial diameter among healthy Japanese participants with different mitochondrial aldehyde dehydrogenase 2 genotypes: randomised crossover trial by Sakata, Satoko et al.
Differential effects of organic nitrates on
arterial diameter among healthy
Japanese participants with different
mitochondrial aldehyde dehydrogenase
2 genotypes: randomised crossover trial
Satoko Sakata,
1 Tatsuya Yoshihara,
2 Hisatomi Arima,
3 Fumie Shiraishi,
2
Hideyuki Oniki,
1 Fumi Takahashi-Yanaga,
2 Kiyoshi Matsumura,
1
Toshiyuki Sasaguri
2
ABSTRACT
Objectives: To determine whether polymorphisms at
codon 487 (*1, GAA¼Glu; *2, AAA¼Lys) of
mitochondrial aldehyde dehydrogenase 2 (ALDH2)
inﬂuence nitroglycerine (glyceryl trinitrate
(GTN))-induced vasodilation, and whether GTN or
isosorbide dinitrate (ISDN) is a more effective
antianginal agent in each ALDH2 genotype.
Design: A randomised, open-label, crossover trial with
117 healthy Japanese (20e39 years) whose genotypes
were determined (*1/*1, n¼47; *1/*2, n¼48; *2/*2,
n¼22) was performed at Kyushu University Hospital,
Fukuoka, Japan. Participants were randomly assigned
to treatment: sublingual spray of GTN (0.3 mg) or
ISDN (1.25 mg). After $1 week, measurements were
repeated using the other drug. The main outcome
measures were the maximal rate of increase in the
brachial artery diameter determined by
ultrasonography, the time required to attain maximal
dilation (Tmax) and the time required to attain 90%
maximal dilation (T0.9).
Results: The maximal artery diameter increase in
response to GTN or ISDN did not differ among
genotypes. However, GTN Tmax was signiﬁcantly
longer for *2/*2 (299.7 s, 269.0e330.4) than *1/*1
(254.7 s, 238.6e273.4; p¼0.0190). GTN T0.9 was
signiﬁcantly longer in the *1/*2 (206.1 s,
191.7e219.3) and *2/*2 (231.4 s, 211.8e251.0)
genotypes than *1/*1 (174.9 s, 161.5e188.3;
p¼0.0068, p<0.0001, respectively). In contrast, the
time-course of ISDN-induced vasodilation did not
differ among genotypes. GTN Tmax and T0.9 among *1
allele carriers (*1/*1 and *1/*2) were signiﬁcantly
shorter than those of ISDN, whereas the time course of
GTN and ISDN vasodilation did not differ among
participants carrying *2/*2.
Conclusions: The amplitude of GTN-induced
vasodilation was not inﬂuenced by the ALDH2
genotype, but the response was signiﬁcantly delayed in
*2 allele carriers, especially *2/*2. GTN dilated the
artery more quickly than ISDN in *1/*1 and *1/*2, but
not in *2/*2.
Trial registration number: UMIN000001492
(UMIN-CTR database).
INTRODUCTION
Nitroglycerine (glyceryl trinitrate (GTN)) has
been the drug of choice to relieve angina
pectoris since 1879 when William Murrell
published his results on the clinical effect of
GTN.
1 However, the effectiveness of GTN is
not consistent among individual patients.
2 A
sublingual 0.3 mg dose of GTN typically
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ARTICLE SUMMARY
Article focus
- There were few reliable human studies on the
inﬂuence of aldehyde dehydrogenase 2 (ALDH2)
polymorphisms at codon 487 on the response to
nitroglycerine (GTN). In particular, there was no
information about the response to GTN in *2/*2
homozygotes.
- It was unclear whether GTN or isosorbide
dinitrate (ISDN) is a more effective antianginal
agent in each ALDH2 genotype.
- We aimed at comparing vasodilation induced by
GTN and ISDN in individuals with different
ALDH2 genotypes.
Key messages
- The maximal rate of increase in arterial diameter
after GTN treatment did not differ among ALDH2
genotype groups.
- The time required to attain 90% maximal
vasodilation was longer in the *1/*2 and *2/*2
groups than in the *1/*1 group.
- GTN (0.3 mg) induced vasodilation more rapidly
than ISDN (1.25 mg) in the *1/*1 and *1/*2
groups, but there was no difference between
GTN and ISDN in the *2/*2 group.
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Open Access Researchalleviates chest pain, but some patients require a larger
dose or repeated administration. The reason for this
differential effect may be complex, since several biolog-
ical processes are involved in mediating the pharmaco-
logical effects of GTN. GTN is a prodrug that must be
reduced to glyceryl dinitrate to generate nitrite, which
is further reduced to nitric oxide (NO). NO is the active
metabolite that relaxes vascular smooth muscle by
stimulating soluble guanylate cyclase to produce cyclic
guanosine monophosphate.
34Proposed mechanisms
for GTN bioactivation include the non-enzymatic inter-
action with thiol compounds such as cysteine and
N-acetylcysteine,
5 and an enzymatic reaction such as
glutathione S-transferase
6e8 and cytochrome P450
89 ;
however, the relative importance of these mechanisms
had not been understood until recently.
In 2002, Chen et al
10 identiﬁed mitochondrial
aldehyde dehydrogenase 2 (ALDH2) as an important
enzyme for GTN bioactivation.
11 They puriﬁed a protein
fraction able to metabolise
14C-GTN and sequenced its
amino acids.
10 Subsequently, they showed that ALDH2
was essential for GTN metabolism using ALDH2
knockout mice.
12 They performed additional in vivo
experiments in dogs to demonstrate the role of ALDH2
in GTN bioactivation.
13 These ﬁndings were supported
by clinical studies. Mackenzie et al
14 reported that the
effect of GTN administered by intra-arterial injection was
33% lower in healthy volunteers if the ALDH2 inhibitor
disulﬁram was given. The loss-of-function single nucle-
otide polymorphism at codon 487 of ALDH2, in which
Glu (GAA, *1) is replaced with Lys (AAA, *2), is
common in East Asian populations including Japanese.
In an in vitro assay, the GTN reductase activity of ALDH2
*2 was shown to be two orders of magnitude lower than
that of the wild-type enzyme.
10 15 Therefore, Mackenzie
et al
14 evaluated the effect of GTN in 11 Asian *2 allele
carriers (*1/*2 and *2/*2) and found that it was 40%
lower than its effect in carriers of *1/*1. Li et al
16
reported that the effect of sublingual GTN was signiﬁ-
cantly lower in *2 allele carriers than in *1/*1 carriers
among Chinese patients with angina; however, it is
unclear whether this decrease in sensitivity to GTN
should be considered in medical practice. Furthermore,
the sensitivity to GTN of *2/*2 carriers should be
distinguished from that of *1/*2 carriers, since the
number of *2/*2 carriers included in previous studies
was too small to be independently analysed. It is
unknown whether another drug may be more effective
for *2/*2 patients. In Japan, isosorbide dinitrate (ISDN)
is the only alternative to GTN available for sublingual
administration during anginal attacks. Since bioactiva-
tion of ISDN appears to be mediated by cytochrome
P450 but not ALDH2,
91 7we wanted to compare the
effectiveness of GTN and ISDN in individuals with
different ALDH2 polymorphisms.
To answer these questions, we conducted a rando-
mised crossover study to compare the vasodilation effect
of GTN with that of ISDN in healthy young Japanese
participants, including sufﬁcient numbers of each
ALDH2 genotype.
METHODS
Study design
From September 2009 to May 2010, we performed this
randomised, open-label, crossover trial at Kyushu
University Hospital, Fukuoka, Japan with volunteers
whose ALDH2 genotypes were determined. After an
initial treatment with a standard therapeutic dose of
either GTN (0.3 mg) or ISDN (1.25 mg), the brachial
artery diameter was continuously measured by ultraso-
nography. After $1 week, the participants received the
other drug, and the measurements were repeated. The
main outcome measures were the maximal rate of
diameter increase, the time required to attain maximal
dilation (Tmax) and the time required to attain 90% of
maximal dilation (T0.9).
Participants
From April 2009 to March 2010, we recruited Japanese
men and women (20e39 years old) among the students
and staff of Kyushu University for participation in the
study, and selected the ﬁnal participants based on
ALDH2 genotype. Persons who met the following
criteria were excluded: (1) requiring treatment for
a disease, (2) under medical treatment, (3) history of
cardiovascular disease, (4) serious liver damage, (5)
serious renal damage, (6) pregnancy, (7) history of
adverse reaction to an organic nitrate, (8) receiving
phosphodiesterase-5 inhibitors (sildenaﬁl, vardenaﬁl or
tadalaﬁl), (9) systolic blood pressure <90 mm Hg, (10)
body weight <40 kg or >90 kg or (11) judged by the
principal investigator (TS) to be inappropriate for
participation in the study.
ARTICLE SUMMARY
Strengths and limitations of this study
- The choice of healthy young individuals as participants may
have strengthened the validity of the study; the participants’
backgrounds were likely to be more homogeneous by
excluding the inﬂuence of multiple concomitant factors that
could not be controlled when studying patients or older
subjects. However, the results could have been different if the
study had been performed with patients with angina, because
haemodynamic changes in patients might alter the response to
nitrates.
- Sublingual spray formulations of nitrates were used instead of
tablets to minimise the ﬂuctuation in absorption rate. However,
this may have made the dosage slightly unreliable.
- A randomised crossover design was used, and arterial
diameter was determined by a single measurer blinded to
genotype. However, the participants and investigators were not
blinded to treatment.
- Arterial diameter was accurately measured using a
semiautomatic ultrasonography system. However, the brachial
artery diameter was measured instead of the coronary
artery diameter, and moreover, we did not evaluate venous
dilation.
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Organic nitrate-induced vasodilation and ALDH2 genotypeGenotyping
Genomic DNA was extracted from peripheral blood with
a DNA isolation kit (GenTLE; Takara Bio, Ohtsu, Japan);
for the 11 participants who did not wish to have blood
drawn, DNA was extracted from saliva with a DNA
self-collection kit (Oragene; DNA Genotek, Ottawa,
Canada). DNA extraction was carried out with the kits
according to the manufacturers’ instructions. ALDH2
genotypes at codon 487 were determined by PCR and
restriction fragment length polymorphism analysis. The
PCR primer sequences were 59-TTGGTGGCTACAA-
GATGTCG-39 (forward) and 59-AAACACTGATGGCCT-
CAAGC-39 (reverse). The 324-bp PCR products were
digested with TspRI (New England BioLabs, Ipswich,
Massachusetts) at 658C for 20 min. The restriction digest
cut the *1 genotype DNA into three fragments (68, 255
and 1 bp) and the *2 genotype DNA into two fragments
(323 and 1 bp), which were separated on a 3% agarose
gel and visualised with ethidium bromide. Genotypes
were determined by the existence of 255 bp and/or
323 bp fragments.
Interventions and outcome measures
Participants were prohibited from drinking alcohol and
smoking cigarettes the night before testing, but meals
were not restricted. After spending at least 60 min
without exercise, participants were randomly assigned
1:1 to a single sublingual spray administration of GTN
(0.3 mg; Myocor spray, Toa Eiyo, Tokyo, Japan) or ISDN
(1.25 mg; Nitorol spray, Eisai Co, Tokyo, Japan) as initial
treatment. A random allocation sequence was made by
HA using random digits generated by the Mersenne
Twister method
18 and conveyed to the investigators (SS,
TY, HO and TS) by sealed numbered envelopes, one for
each participant, with instructions to use the envelopes
in numerical order. Participants rested at least 5 min in
a supine position in a quiet examination room at 248C,
and then the right brachial artery was scanned in
a longitudinal section 1 to 10 cm above the elbow in an
arm maintained in the same position throughout the
study, with a 10 MHz linear array transducer probe. To
determine the maximal diameter of the artery, the
end-diastolic diameter (length from one side of the
mediaeadventitia interface to the other side) coincident
with the R-wave on a monitoring electrocardiogram was
continuously measured from 30 s before nitrate admin-
istration to 10 min after administration. This measurement
was performed using a semiautomatic high-resolution
B-mode ultrasound imaging system (UNEX EF 18G II,
UNEX Corporation, Nagoya, Japan)
19 20 by a single
expert (SS) blinded to genotype and recorded on a hard
disk. Pulse rate and blood pressure were measured every
5 min. More than 7 days later, each participant received
the other drug, and the measurements were repeated.
The prespeciﬁed primary outcome measures were the
maximal rate of increase in brachial artery diameter and
the time required to attain maximal dilation (Tmax).
However, the time required to attain 90% maximal
dilation (T0.9) was also determined, so as to minimise
ﬂuctuation of the outcome measure. In addition,
changes in pulse rate and blood pressure were assigned
as secondary outcome measures.
Statistical analysis
The minimum sample size for this clinical trial was based
on results obtained in previous studies. The mean and
SD for the increase in forearm blood ﬂow induced by
GTN in *1/*1 and *2 allele carriers were reported
by Mackenzie et al.
14 Because no data were available
regarding the homozygous *2/*2 population, we esti-
mated the mean and SD values based on an experiment
by Chen et al
12 using ALDH2 knockout mice. According
to their results, we assumed that the increase in blood
ﬂow in *1/*1 and *2/*2 genotypes was 4.563.36 and
1.961.99 (ml/100 ml/min), respectively. Power calcula-
tion indicated that the minimum sample sizes of *1/*1
versus *2/*2 carriers were 24:24, 27:19, 30:15, 37:13
or 43:11 to detect the difference (2.6 ml/100 ml/min)
between these two genotypes with a statistical power of
90% and a p value of 0.05. The resultant sample size
(*1/*1, n¼47; *2/*2, n¼22) had an 80% power to
detect a minimal difference of 3.7% in arterial diameter
change in response to nitrates between these groups.
Likewise, there was an 80% power to detect a minimal
difference of 35 s in time required for arterial dilation
between the two genotypes.
Differences in baseline characteristics of participants
were compared according to genotype, using the c
2 test
for the categorical variable and one-way analysis of
variance (ANOVA) for continuous variables. Primary
outcome measures were displayed according to genotype
group using box-and-whisker plots. Overall group
differences in the primary and secondary outcomes were
determined by one-way ANOVA and analysis of covari-
ance (ANCOVA) with sex, age, body mass index and
systolic blood pressure as covariates. The TukeyeKramer
test was used for multiple comparisons. Differences in
outcomes between GTN and ISDN were also determined
by one-way ANOVA and ANCOVA with the same cova-
riates in each genotype. All data were analysed with
SAS version 9.2. A p value of <0.05 was considered
signiﬁcant.
RESULTS
The frequency of the ALDH2 *2 allele is approximately
20% in the Japanese population, although regional
differences may exist.
21 The frequencies of each geno-
type are: *1/*1, 60% to 70%; *1/*2, 30% to 40%; and
*2/*2, 3% to 5%. To overcome the difﬁculty of
recruiting enough *2/*2 homozygotes by random
screening only, we intentionally recruited participants
who were unable to drink alcohol by advertisement at
Kyushu University. We analysed genotypes of 305 indi-
viduals (*1/*1, n¼156; *1/*2, n¼111; *2/*2, n¼38) and
included 117 individuals in the trial to fulﬁl the required
sample size (*1/*1, n¼47; *1/*2, n¼48; *2/*2, n¼22).
As shown in table 1, baseline characteristics did not
differ among the genotype groups. We analysed the
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Organic nitrate-induced vasodilation and ALDH2 genotypeoutcomes from all the participants without loss or
exclusion.
Initially, we planned to assess the effectiveness of
nitrates primarily with two parameters: (1) the maximal
rate of increase in brachial artery diameter (Dmax D0)/
D0, where D0 is the diameter at time 0, and Dmax is the
maximal diameter achieved after nitrate administration;
a n d( 2 )t h et i m er e q u i r e dt oa ttain maximal dilation (Tmax).
Unexpectedly, the ﬁrst parameter (Dmax D0)/D0 did
not differ among the genotype groups after either
treatment (ﬁgure 1), even after adjusting for sex, age,
body mass index and systolic blood pressure. This
ﬁnding suggests that GTN and ISDN eventually produce
the same level of vasodilation regardless of genotype.
We then analysed the second parameter, Tmax.A s
shown in ﬁgure 2, the GTN Tmax was signiﬁcantly longer
in the *2/*2 genotype group than in the *1/*1 group
(crude data, p¼0.0190; adjusted data, p¼0.0234), but
no signiﬁcant difference was observed between the
*1/*1 and *1/*2 groups (crude, p¼0.1390; adjusted,
p¼0.1834). The p trend among the three genotypes
was signiﬁcant for both crude (p¼0.004) and adjusted
(p¼0.0002) data. In contrast, ISDN Tmax did not differ
among the genotype groups.
Table 1 Baseline characteristics of the participants
Total *1/*1 *1/*2 *2/*2 p Value
No 117 47 48 22
Male (%) 72.7 72.3 70.8 77.3 0.85
Age (years) 26.664.3 25.864.0 26.864.3 28.064.8 0.11
Height (cm) 167.568.4 168.068.5 168.168.1 165.068.9 0.41
Weight (kg) 59.669.3 59.968.5 59.9610.4 57.768.4 0.62
Body mass index 21.262.3 21.362.1 21.162.7 21.161.9 0.91
Pulse rate (beats/min) 65.8610.9 64.5610.4 64.9610.1 65.9611.7 0.99
Systolic blood pressure (mm Hg) 119.5611.8 118.4613.5 117.0612.5 118.3610.9 0.60
Diastolic blood pressure (mm Hg) 67.168.4 66.768.7 65.968.1 64.366.8 0.42
Demographic and physiological parameters of the participants were evaluated by c
2 test for sex and by one-way ANOVA for body mass index,
pulse rate, systolic blood pressure and diastolic blood pressure. Results are expressed as mean6SD.
Figure 1 Maximal rate of increase in the brachial artery
diameter. After sublingual administration of glyceryl trinitrate
(GTN) (0.3 mg) or isosorbide dinitrate (ISDN) (1.25 mg), the
brachial artery diameter was measured continuously for
10 min. The maximal rate of increase was calculated by the
formula (Dmax D0)/D0, where D0 was the baseline diameter,
and Dmax was the maximal diameter achieved. The values of
(Dmax D0)/D0 after GTN treatment were: total, 0.188
(0.178e0.199); *1/*1 genotype, 0.176 (0.163e0.196); *1/*2
genotype, 0.195 (0.177e0.210); and *2/*2 genotype, 0.196
(0.172e0.221). The values of (Dmax D0)/D0 after ISDN
treatment were: total, 0.187 (0.178e0.196); *1/*1 genotype,
0.183 (0.169e0.199); *1/*2 genotype, 0.189 (0.174e0.204); *2/
*2 genotype, 0.189 (0.167e0.210). Results are shown as box-
and-whisker plots indicating the 10th, 25th, 50th, 75th and 90th
percentiles. Group results were compared by one-way ANOVA
for crude data and by ANCOVA after adjusting for sex, age,
body mass index and systolic blood pressure.
Figure 2 Time required to attain maximal dilation (Tmax).
After sublingual administration of glyceryl trinitrate (GTN)
(0.3 mg) or isosorbide dinitrate (ISDN) (1.25 mg), the brachial
artery diameter was measured continuously for 10 min. The
values of the time when Dmax was achieved (Tmax) after GTN
treatment were: total, 272.6 s (261.4e284.2 s); *1/*1 genotype,
254.7 s (238.6e273.4 s); *1/*2 genotype, 277.4 s
(259.4e294.3 s); *2/*2 genotype, 299.7 s (269.0e330.4 s).
Tmax values after ISDN treatment were: total, 351.4 s
(337.6e368.7 s); *1/*1 genotype, 365.0 s (340.5e389.9 s);
*1/*2 genotype, 340.3 s (316.2e364.5 s); *2/*2 genotype,
347.0 s (320.7e391.3 s). Results for the different genotypes
and nitrate treatments are shown as box-and-whisker plots
indicating the 10th, 25th, 50th, 75th and 90th percentiles.
Group results were compared by one-way ANOVA for crude
data and by ANCOVA after adjusting for sex, age, body mass
index and systolic blood pressure.
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Organic nitrate-induced vasodilation and ALDH2 genotypeThe brachial artery typically began to dilate about
1 min after nitrate administration. The diameter rapidly
increased until 3 min, after which dilation slowed, and
the diameter reached the maximum size at 4 to 6 min.
However, it was often not easy to determine Tmax,
because the artery diameter usually approached the
maximum size slowly. Thus, an artefact in the trace could
signiﬁcantly affect the determination of Tmax. To avoid
this problem, we introduced the parameter T0.9, which is
the time point at which the arterial diameter reached
90% of the maximal level, to minimise ﬂuctuation of the
outcome measure.
As shown in ﬁgure 3, GTN T0.9 was signiﬁcantly longer
in participants with *2/*2 (crude, p<0.0001; adjusted,
p¼0.0002) and *1/*2 (crude, p¼0.0068; adjusted,
p¼0.0157) genotypes than those with *1/*1. The p
trend among the three genotypes was also signiﬁcant
(crude, p<0.0001; adjusted, p<0.0001). On the other
hand, there was no difference in the T0.9 of ISDN. A
similar result was obtained when the time required for
50% maximal dilation was analysed (supplementary
online ﬁgure).
Next we investigated which organic nitrate was more
effective in each ALDH2 genotype. As shown in ﬁgure 1,
the effects of GTN and ISDN on (Dmax D0)/D0 did not
differ in any genotype group. In contrast, the Tmax of
GTN was signiﬁcantly smaller than that of ISDN in the
*1/*1 group (crude, p<0.0001; adjusted, p<0.0001) and
*1/*2 group (crude, p<0.0001; adjusted, p<0.0001), but
no difference was observed between the effects of these
nitrates in the *2/*2 group (crude, p¼0.0972; adjusted,
p¼0.1023) (ﬁgure 2). The T0.9 of GTN was also signiﬁ-
cantly smaller than that of ISDN in the *1/*1 group
(crude, p<0.0001; adjusted, p<0.0001) and *1/*2 group
(crude, p¼0.0039, adjusted, p¼0.0013), but this value
did not differ between the treatments in the *2/*2
group (crude, p¼0.1996, adjusted, p¼0.3122) (ﬁgure 3).
The results of secondary outcome measures are
summarised in the supplementary online table. No
signiﬁcant differences were observed in pulse rate, dia-
stolic blood pressure or systolic blood pressure measured
10 min after nitrate administration among the ALDH2
genotype groups. Further, no serious adverse events were
observed throughout the study.
DISCUSSION
Principal ﬁndings
First, the maximal rate of increase in diameter after GTN
treatment did not differ among ALDH2 genotype
groups, suggesting that GTN eventually induces maximal
vasodilation regardless of genotype. Second, the GTN
Tmax was signiﬁcantly longer in the *2/*2 group than in
the *1/*1 group, and GTN T0.9 was signiﬁcantly longer
in the *1/*2 and *2/*2 groups than in the *1/*1 group,
suggesting that the *1 allele is associated with a more
rapid response to GTN. However, this differential
response was not observed after ISDN treatment. Third,
GTN (0.3 mg) induced vasodilation more rapidly than
ISDN (1.25 mg) in the *1/*1 and *1/*2 groups, but the
Tmax and T0.9 values of GTN and ISDN did not differ in
the *2/*2 group.
Strengths and limitations of the study
This study was carefully designed and conducted;
however, our results require careful interpretation. First,
the study participants were not patients with angina.
Healthy, young volunteers were used because organic
nitrates can also induce vasodilation in healthy people.
The choice of participants may have strengthened the
validity of the study; the participants’ backgrounds were
likely to be more homogeneous by excluding the inﬂu-
ence of multiple concomitant factors that could not be
controlled when studying patients or older subjects. In
addition, using healthy, young participants made it easy
to recruit a large enough sample of *2/*2 homozygotes.
However, the results could have been different if the
study had used patients with angina, because haemody-
namic changes in patients might alter the response to
organic nitrates. Second, we used sublingual spray
formulations instead of tablets for both nitrates to
minimise the ﬂuctuation in absorption rate. However,
this may have made the dosage slightly unreliable,
22
although this would have affected all the participants
similarly and therefore should not have biased the
results. Third, to minimise bias, a randomised crossover
design was used, and arterial diameter was determined
by a single measurer blinded to genotype. However, the
participants and investigators were not blinded to
Figure 3 Time required to attain 90% maximal dilation (T0.9).
After sublingual administration of glyceryl trinitrate (GTN)
(0.3 mg) or isosorbide dinitrate (ISDN) (1.25 mg), the brachial
artery diameter was measured continuously for 10 min. The
values of the time at which the diameter achieved 90% Dmax
(T0.9) after GTN treatment were: total, 198.3 s
(189.0e207.6 s); *1/*1 genotype, 174.9 s (161.5e188.3 s);
*1/*2 genotype, 206.1 s (191.7e219.3 s); *2/*2 genotype,
231.4 s (211.8e251.0 s). T0.9 values after ISDN treatment:
total, 242.0 s (231.6e254.2 s); *1/*1 genotype, 236.8 s
(220.8e257.0 s); *1/*2 genotype, 244.7 s (227.0e262.5 s);
*2/*2 genotype, 247.4 s (221.5e273.3 s). Results for the
different genotypes and nitrate treatments are shown as box-
and-whisker plots indicating the 10th, 25th, 50th, 75th and 90th
percentiles. Group results were compared by one-way ANOVA
for crude data and by ANCOVA after adjusting for sex, age,
body mass index and systolic blood pressure.
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Organic nitrate-induced vasodilation and ALDH2 genotypetreatment. Fourth, arterial diameter was accurately
measured using a semiautomatic ultrasonography
system.
19 20 However, the brachial artery diameter was
measured instead of the coronary artery diameter.
Moreover, we did not evaluate venous dilation, although
venodilation is thought to be a mechanism that is as
important as coronary artery dilation for the antianginal
effects of nitrates.
32 32 4
Comparison with other studies
Other than the present study, three previous clinical
studies have investigated the inﬂuence of the ALDH2
polymorphism on GTN effects, but the study performed
by Mackenzie et al
14 was the only experimental study
(clinical trial). In that study, GTN was injected into the
brachial artery of healthy participants, and forearm
blood ﬂow measured by venous occlusion plethysmog-
raphy was 33% lower if the ALDH2 inhibitor disulﬁram
was administered. Analysing 16 healthy East Asian
participants (*1/*1, n¼5; *1/*2, n¼9; *2/*2, n¼2), they
also showed that the effect of GTN was 40% lower in
carriers of the *2 allele than in participants with the
*1/*1 genotype. However, the analysis did not differen-
tiate between *1/*2 and *2/*2 genotypes, probably
because the sample size was too small. In contrast, the
present study included enough participants to allow
analysis of the *2/*2 population. Moreover, we used
ultrasonography to assess arterial dilation, which is
a more direct method than plethysmography. The other
two studies were both observational studies. Li et al
16
divided 80 Chinese patients with stable angina according
to whether pain relief, assessed using a pain judgement
scale, was obtained within 10 min after sublingual
administration of GTN. ALDH2 genotypes of each group
were then analysed, revealing that the effect of GTN was
signiﬁcantly smaller in carriers of the *2 allele than in
participants with the *1/*1 genotype. Zhang et al
25
reported that in 142 Chinese patients with coronary
heart disease, the rate of efﬁcacious response to GTN
was signiﬁcantly higher in patients with the *1/*1
genotype than in those carrying the *2 allele. However,
these studies did not distinguish between the *1/*2 and
*2/*2 genotypes. Moreover, the efﬁcacy of GTN was
assessed according to the patients’ subjective reporting
of symptoms, potentially introducing bias. Therefore,
few reliable human studies on the inﬂuence of the
ALDH2 polymorphisms on the response to GTN were
available until our study was conducted; in particular,
there was no information about the response to GTN in
*2/*2 homozygotes.
Based on the earlier studies, we initially hypothesised
that the maximal response to GTN would be reduced in
*2 allele carriers, but the results obtained were different
from our expectation. Although the time required to
obtain the response was different among the genotype
groups, there was no difference in the size of response
(the reason for this is discussed later). However, we
cannot specify the reason for the difference in the results
between earlier studies and ours. Probably multiple
factors may be involved, such as study design, sample
size, GTN dosage, studied vascular beds, measurement
method or outcome measures.
Meaning of the study
The results of this study may have clinical implications for
the daily use of organic nitrates. First, although there was
no signiﬁcant difference in the magnitude of response to
GTN, the delay in attaining near maximal dilation was
about 1 min for *2/*2 participants who took 0.3 mg of
GTN. Given that the purpose of GTN is to provide rapid
relief for chest pain, we believe that a 1 min delay cannot
be ignored, although we observed only brachial artery
dilation but not disappearance of the symptom. To prac-
tisepersonalisedmedicineforpatientswithangina,itmay
beusefultoknowtheindividualALDH2genotypesbefore
treatment. If gene analysis is not available, a patient’s
genotype could be estimated by asking about drinking
history or using the ethanol patch test.
26 Second, this
study suggests the ﬁrst choice drug for treating angina in
terms of ALDH2 polymorphisms. Assuming that a rapid
responseisbetter,GTNmaystillbetheﬁrstchoicefor*1/
*1 patients and perhaps also for *1/*2 patients, because
GTN dilated the artery more rapidly than ISDN in
participants with these genotypes. However, ISDN may be
a better choice for *2/*2 patients, because it dilated the
artery as fast as GTN; moreover, larger or repeated doses
of GTN often induce tolerance and oxidative stress,
although ISDN can also cause tolerance.
27 In addition,
this study may also be informative for basic research on
organic nitrate pharmacology. The maximal rate of
diameter increase was comparable among the genotypes.
One explanation for this ﬁnding is that even the small
amount of NO generated by ALDH2 *2 allele is sufﬁcient
formaximalresponse,becausetheGTNreductaseactivity
of ALDH2 *2 is small but not nil.
15 Previously, maximal
relaxation of rat aortic rings was shown to occur at only
3.4% of the maximal levels of cyclic guanosine mono-
phosphate obtained with NO.
28 Another, perhaps more
likely explanation is that enzymes other than ALDH2,
suchasglutathioneS-transferase,
672 9cytochromeP450
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and xanthine oxidoreductase,
30 are also involved in the
bioactivation of GTN. It has been suggested that ALDH2
activates GTN at the low concentrations achieved by
therapeutic doses, whereas cytochrome P450 activates
GTN at higher concentrations.
27 However, our results
suggest that ALDH2 and other enzymes are concurrently
involvedinGTNbioactivation,evenatlowconcentrations
achieved by the standard therapeutic dose. The other
enzymes involved may be able to generate a sufﬁcient
amount of NO without ALDH2, whereas ALDH2 speciﬁ-
cally may be responsible for the rapid generation of NO.
Unanswered questions and future research
First, this study suggested that decreased ALDH2 activity
delayed GTN-induced vasodilation in *2 allele carriers;
however, direct evidence for delayed GTN bioactivation
in *2 allele carriers has not been obtained. Therefore,
pharmacokinetic studies evaluating serum
6 Sakata S, Yoshihara T, Arima H, et al. BMJ Open 2011;1:e000133. doi:10.1136/bmjopen-2011-000133
Organic nitrate-induced vasodilation and ALDH2 genotypeconcentrations of GTN and its metabolites are needed to
speciﬁcally assess whether GTN metabolism is delayed in
*2 allele carriers. Second, we should also evaluate GTN-
induced venous dilation in *2 allele carriers, since an in
vitro experiment showed that venodilation was attenu-
ated by pharmacological inhibition of ALDH2.
31 Third,
the inﬂuence of the ALDH2 polymorphism on the action
of GTN should be investigated with a clinical trial of
patients with angina. No clinical trial has been conducted
with patients so far; however, the study protocol should
be carefully designed to enable precise determination of
outcome measures. Fourth, basic studies are needed to
identify the enzymes other than ALDH2 involved in GTN
metabolism. Finally, it may be necessary to promote the
development of a new medicine that is more beneﬁcial
than GTN.
32 33 This is not simply because the response to
GTN varies among ALDH2 genotypes, but because
repeated or long-term GTN administration may cause
nitrate tolerance inactivating ALDH2 by superoxide
generation,
42 73 4 e36 and moreover, inactivated ALDH2
could disturb cardiovascular cell functions.
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